Diabetes mellitus type 2 and cancer share many risk factors.The pleiotropic insulin-dependent and insulin-independent effects of metformin might inhibit pathways that are frequently amplified in neoplastic tissue.Part...Diabetes mellitus type 2 and cancer share many risk factors.The pleiotropic insulin-dependent and insulin-independent effects of metformin might inhibit pathways that are frequently amplified in neoplastic tissue.Particularly,modulation of inflammation,metabolism,and cell cycle arrest are potential therapeutic cancer targets utilized by metformin to boost the anti-cancer effects of chemotherapy.Studies in vitro and in vivo models have demonstrated the potential of metformin as a chemo-and radiosensitizer,besides its chemopreventive and direct therapeutic activity in digestive system(DS)tumors.Hence,these aspects have been considered in many cancer clinical trials.Case-control and cohort studies and associated meta-analyses have evaluated DS cancer risk and metformin usage,especially in colorectal cancer,pancreatic cancer,and hepatocellular carcinoma.Most clinical studies have demonstrated the protective role of metformin in the risk for DS cancers and survival rates.On the other hand,the ability of metformin to enhance the actions of chemotherapy for gastric and biliary cancers is yet to be investigated.This article reviews the current findings on the anti-cancer mechanisms of metformin and its apparatus from pre-clinical and ongoing studies in DS malignancies.展开更多
文摘Diabetes mellitus type 2 and cancer share many risk factors.The pleiotropic insulin-dependent and insulin-independent effects of metformin might inhibit pathways that are frequently amplified in neoplastic tissue.Particularly,modulation of inflammation,metabolism,and cell cycle arrest are potential therapeutic cancer targets utilized by metformin to boost the anti-cancer effects of chemotherapy.Studies in vitro and in vivo models have demonstrated the potential of metformin as a chemo-and radiosensitizer,besides its chemopreventive and direct therapeutic activity in digestive system(DS)tumors.Hence,these aspects have been considered in many cancer clinical trials.Case-control and cohort studies and associated meta-analyses have evaluated DS cancer risk and metformin usage,especially in colorectal cancer,pancreatic cancer,and hepatocellular carcinoma.Most clinical studies have demonstrated the protective role of metformin in the risk for DS cancers and survival rates.On the other hand,the ability of metformin to enhance the actions of chemotherapy for gastric and biliary cancers is yet to be investigated.This article reviews the current findings on the anti-cancer mechanisms of metformin and its apparatus from pre-clinical and ongoing studies in DS malignancies.
